Revenue
2024
2025
Pelthos Therapeutics Inc. (PTHS)
Price—Loading quote
Net income
2022
2023
2024
2025
Free cash flow
2024
2025
Total cash / debt
CashTotal debt
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $16.8M | $0 | — | — |
| Research & development | $1.2M | $1.2M | $2.6M | $391,730 |
| Operating expenses | — | $7.6M | $6.9M | $2.3M |
| Operating income | −$32.4M | −$7.6M | −$6.9M | −$2.3M |
| EBITDAderived | −$30.1M | −$7.6M | — | — |
| Net income | −$43.3M | −$8.0M | −$7.4M | −$2.5M |
| Basic EPSper diluted share | -$23.04 | -$14.27 | -$5.78 | $5.65 |
| Diluted EPSper diluted share | -$23.04 | -$14.27 | -$5.78 | — |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 15, 2026Form 4 · 10b5-1 | Friedberg Ezra MDirector | SellCommon Stock | 59 | $27.94 | $1.6K | 81.6K |
| Jun 15, 2026Form 4 · 10b5-1 | Friedberg Ezra MDirector | SellCommon Stock | 224 | $27.12 | $6.1K | 81.7K |
| Jun 11, 2026Form 4 | Davis Todd CDirector | BuyCommon Stock | 503 | $28.73 | $14.5K | 75.8K |
| Jun 11, 2026Form 4 | Davis Todd CDirector | BuyCommon Stock | 35.4K | $27.80 | $985.4K | 75.3K |
| May 22, 2026Form 4 | Francis Knuettel IICFO, Treas & Secty | SellCommon Stock · indirect | 1.5K | $26.84 | $40.3K | 11.3K |